Normal Tension Glaucoma

01Pathophysiology

Normal tension glaucoma (NTG) is classified as a subtype of primary open-angle glaucoma (POAG) in which the defining paradox is progressive optic nerve damage occurring at an IOP that falls within the statistically normal range (≤ 21 mmHg). This challenges the traditional understanding that elevated IOP is the sole driver of glaucomatous damage and shifts the focus toward non-pressure-dependent mechanisms.The predominant theory involves vascular dysregulation at the optic nerve head. In NTG patients, the autoregulatory mechanisms that maintain stable blood flow to the optic disc are impaired. When systemic blood pressure drops, particularly during sleep (nocturnal hypotension), perfusion pressure to the optic nerve head falls below a critical threshold, resulting in ischemic injury to the retinal ganglion cells. This explains the strong association with Raynaud phenomenon and migraine, both of which reflect systemic vasospastic tendencies. The concept of optic nerve perfusion pressure, defined as the difference between mean arterial pressure and IOP, is central here. Even a "normal" IOP can be relatively too high for an optic nerve that is already underperfused.

A second contributing mechanism involves mechanical susceptibility of the lamina cribrosa. In some NTG patients, the connective tissue architecture of the lamina cribrosa is structurally weaker, meaning even normal levels of IOP can produce axonal compression and disruption of axoplasmic flow. This leads to retinal ganglion cell apoptosis through mechanisms analogous to high-pressure glaucoma but at a lower threshold.

Additionally, there is growing evidence for translaminar pressure gradient abnormalities. The pressure difference between the intraocular compartment (IOP) and the retrolaminar cerebrospinal fluid (CSF) pressure determines the net mechanical stress on the lamina. NTG patients have been found to have lower intracranial pressure (ICP), which means the translaminar gradient is higher even when IOP is normal, effectively producing the same axonal stress as elevated IOP would in a patient with normal ICP.

Finally, oxidative stress, glutamate excitotoxicity, and autoimmune-mediated damage to retinal ganglion cells have been proposed as additional IOP-independent pathways. These mechanisms are less firmly established but are under active investigation and occasionally appear in exam questions framed around "non-IOP-dependent risk factors."

The clinical consequence of all these mechanisms is the same: progressive, irreversible loss of retinal ganglion cell axons leading to characteristic optic disc cupping and visual field defects that are often more centrally located (paracentral scotomas) compared to the more peripheral arcuate defects seen in high-pressure POAG.

02Classification and Clinical Manifestation

NTG is not traditionally subclassified into formal stages the way some diseases are, but it is critical to understand where it sits within the glaucoma classification and how its clinical features differ from related conditions.

Glaucoma Classification

Clinical Manifestations of NTG

The clinical pearl here is that disc hemorrhages and paracentral scotomas closer to fixation are hallmark features that should raise suspicion for NTG over typical POAG on a vignette.

03Diagnostic Workup

Diagnostic Summary Table

The best initial step when glaucomatous disc changes are observed is to confirm the IOP with Goldmann applanation tonometry on multiple occasions. A single normal reading is insufficient because IOP fluctuates throughout the day. A diurnal curve (measurements taken at different times including early morning) is essential to ensure there are no occult pressure spikes that would reclassify the patient as having standard POAG.

Pachymetry is a required adjunct. Central corneal thickness directly affects the accuracy of tonometry. A thin cornea will cause Goldmann tonometry to underestimate the true IOP, meaning some patients labeled as "NTG" may actually have a higher true IOP. Conversely, thin corneal thickness has been shown in the Ocular Hypertension Treatment Study (OHTS) and the Collaborative Normal-Tension Glaucoma Study (CNTGS) to be an independent risk factor for glaucomatous progression.

Gonioscopy is non-negotiable. Every patient with suspected glaucoma must have their angle assessed to exclude angle-closure mechanisms, pigment dispersion, or pseudoexfoliation that might explain the disc damage.

Visual field testing with standard automated perimetry (Humphrey visual field, typically 24-2 strategy) is the functional gold standard for documenting the pattern and severity of field loss. In NTG, the 10-2 test (which focuses on the central 10 degrees) is particularly valuable because paracentral defects closer to fixation are more common than in high-pressure POAG and may be missed on a 24-2 test.

OCT provides objective, quantitative measurement of the RNFL and ganglion cell layer and is invaluable for detecting early structural damage before visual field loss becomes clinically apparent on perimetry.

A critical diagnostic consideration: always rule out non-glaucomatous causes of optic disc cupping and visual field loss. If the presentation is atypical (unilateral, rapidly progressive, visual field defect respecting the vertical midline suggesting a neurologic rather than glaucomatous pattern, or presence of pallor out of proportion to cupping), MRI of the brain and orbits must be obtained to exclude compressive lesions such as pituitary adenomas, meningiomas, or aneurysms. This is a high-yield exam trap.

04Management and Treatment

Management Summary Table

Despite the IOP being "normal," the Collaborative Normal-Tension Glaucoma Study (CNTGS) demonstrated that lowering IOP by 30% from baseline significantly reduces the rate of visual field progression. This established IOP reduction as the evidence-based treatment for NTG, even though the IOP is already within the statistically normal range. The target is not a fixed number but a 30% reduction from the individual's baseline.

Prostaglandin analogs (latanoprost, travoprost, bimatoprost) are first-line because they provide the greatest IOP-lowering efficacy (25-33% reduction), have a favorable once-daily dosing schedule (administered at bedtime), and have minimal systemic side effects. Counsel patients about potential local effects: iris pigmentation changes (particularly in hazel or green eyes), periorbital fat atrophy, and eyelash growth.

If a prostaglandin analog alone does not achieve the target, adjunctive agents are added. Topical timolol is a common second agent (one drop of 0.5% twice daily), but it must be used cautiously. Avoid timolol in patients with asthma, COPD, second- or third-degree heart block, or decompensated heart failure. Brimonidine and dorzolamide are alternatives, often used as fixed-combination drops to reduce the burden of multiple medications.

Selective laser trabeculoplasty (SLT) is an effective option that can be offered as a primary treatment or as an adjunct. It carries minimal risk and can be repeated if the effect wanes over time.

For patients who continue to progress despite maximal tolerated medical and laser therapy, trabeculectomy (filtration surgery) is considered. This creates a new drainage pathway for aqueous humor, further lowering IOP, but carries risks of hypotony, bleb-related infection, and cataract formation.

An often-overlooked component of NTG management involves systemic vascular optimization. Patients on antihypertensive medications who demonstrate nocturnal hypotension should have their dosing schedule reviewed in coordination with their primary care physician. Aggressive nighttime blood pressure lowering can worsen optic nerve perfusion and accelerate NTG progression. This does not mean stopping antihypertensives, but rather adjusting the timing (e.g., switching evening doses to morning) to avoid excessive nocturnal dips. Obstructive sleep apnea should be screened for and treated with CPAP if present.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students miss questions on NTG is by assuming that a normal IOP rules out glaucoma. This is the fundamental conceptual trap. When a vignette describes progressive visual field loss with optic disc cupping and normal IOP, the instinct to look for a non-glaucomatous diagnosis is strong, but the correct answer is almost always NTG, provided the angle is open, the visual field pattern is glaucomatous (not hemianopic), and neuroimaging has been considered.

The second major trap involves failing to order neuroimaging when the presentation is atypical. A young patient with unilateral disc pallor, a visual field defect that respects the vertical midline, or rapid progression should prompt an MRI before accepting the diagnosis of NTG. Test writers love to include a pituitary adenoma masquerading as NTG.

A third pitfall is not understanding pachymetry. Some questions will present a patient with "normal IOP" who actually has a thin cornea. The student must recognize that the measured IOP is artificially low, and the true IOP may be higher. This does not automatically convert the diagnosis to POAG, but it is a testable concept about the limitations of Goldmann tonometry.

Finally, remember that the treatment for NTG is still IOP lowering, even though the IOP is normal. Students sometimes hesitate to choose "lower the IOP" when the pressure is 14 mmHg, but the CNTGS data clearly supports this approach. The target is a relative 30% reduction from baseline, not an absolute threshold. If the baseline IOP is 16 mmHg, the target becomes approximately 11 mmHg.

The core competency being tested across NTG questions is the ability to recognize that glaucomatous damage is not solely defined by elevated IOP, to distinguish NTG from compressive and vascular optic neuropathies, and to apply evidence-based IOP-lowering treatment even in the absence of elevated pressure.